VYGR — Voyager Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $274.57m
- $58.98m
- $80.00m
- 24
- 30
- 26
- 15
Annual cashflow statement for Voyager Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 36.7 | -71.2 | -46.4 | 132 | -65 |
| Depreciation | |||||
| Non-Cash Items | 7.26 | 9.21 | 7.24 | 7.71 | 10.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -145 | 3.29 | 20.5 | -66.6 | 34.9 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -96.7 | -53.5 | -12.5 | 77.9 | -15.3 |
| Capital Expenditures | -12.1 | -1.61 | -2.49 | -3.26 | -3.52 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 125 | 67.5 | -4.85 | -138 | -91.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 113 | 65.9 | -7.34 | -142 | -94.9 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 3.16 | 0.612 | 1.11 | 33.6 | 114 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19.4 | 13 | -18.7 | -30.1 | 3.85 |